Derma Sciences Inc. (DSCI) Hits New 52-week Low During January 20 Session

Equities Staff |

Derma Sciences Inc. (DSCI) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $3.26, Derma Sciences Inc. dropped to $3.20 for a new 52-week low. By the closing bell, the company's stock was at $3.37 a share for a gain of 1.05%.

Falling to a new 52-week low is never fun for company's shareholder, but, depending on who you ask, it can be either a buy or a sell signal. Someone bearish on the stock might see it reaching its lowest price in a year as a sign of growing downward momentum and make sure they sell their shares. Bulls, though, are more likely to see a new 52-week low as the stock hitting its low point and anticipate a bounce in the share price.

However one plays it, it's often a critical moment for any stock and should be noted by investors.

Derma Sciences Inc. saw 314,073 shares of its stock trade hands, that's out of 25.81 million shares outstand. The stock has an average daily volume of 231,392 shares. After hitting a new 52-week low, Derma Sciences Inc. enters the new trading day with a market cap of 86.84 million, a 50-day SMA of $4.38 and a 200-day SMA of $6.08

For a complete fundamental analysis analysis of Derma Sciences Inc., check out’s Stock Valuation Analysis report for DSCI. To see the latest independent stock recommendations from’s analysts, visit our Research section.

Derma Sciences Inc is a tissue regeneration company engaged in pharmaceutical wound care, advanced wound care and traditional wound care products.

Derma Sciences Inc. has 303 employees, is led by CEO , and makes its home in Princeton, NJ.

Derma Sciences Inc. is also a component of the Russell 2000 Index, which is generally viewed as the most reliable indicator of the health of the broader small-cap market. Using a rules-based methodology, it creates a simple, unbiased view of how America's stable of smaller publicly traded companies are performing in the stock markets.

The index consists of the 2,000 smallest companies of the 3,000 largest publicly-traded companies in the country as judged by market cap. It's constructed by Russell Investments, which also builds and maintains the Russell 3000 (an index consisting of all 3,000 biggest companies by market cap) and the large-cap Russell 1000 (which has the 1,000 largest companies from the Russell 3000).

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…